Table 9 |
||||||||
|
Laboratory-based evaluations of safety |
||||||||
|
Test |
Placebo Wk. 0 |
Placebo Wk. 8 |
A Wk. 0 |
A Wk. 8 |
B Wk. 0 |
B Wk. 8 |
C Wk. 0 |
C Wk. 8 |
|
|
||||||||
|
Neu |
62.0 ± 1.7 |
64.2 ± 2.1 |
59.3 ± 2.4 |
58.6 ± 2.3 |
64.7 ± 1.6 |
61.5 ± 1.6 |
61.6 ± 1.5 |
63.0 ± 1.7 |
|
Bas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.3 ± 0.3 |
|
Eos |
3.6 ± 0.8 |
3.6 ± 0.6 |
4.2 ± 0.5 |
3.7 ± 0.9 |
4.0 ± 0.6 |
4.8 ± 1.5 |
3.9 ± 0.5 |
4.4 ± 0.5 |
|
Lym |
34.0 ± 2.0 |
31.7 ± 2.5 |
35.7 ± 2.5 |
35.2 ± 1.8 |
30.3 ± 1.8 |
34.3 ± 1.8* |
33.4 ± 1.7 |
31.8 ± 1.8 |
|
Mon |
0.8 ± 0.3 |
0.6 ± 0.2 |
1.0 ± 0.2 |
0.8 ± 0.3 |
0.9 ± 0.2 |
0.7 ± 0.2 |
1.1 ± 0.2 |
0.7 ± 0.2 |
|
WBC |
8052 ± 417 |
8260 ± 499 |
7994 ± 514 |
8037 ± 655 |
8750 ± 476 |
7857 ± 478 |
8160 ± 308 |
7815 ± 459 |
|
RBC |
3.98 ± 0.09 |
4.11 ± 0.11 |
4.26 ± 0.09 |
4.41 ± 0.12 |
4.33 ± 0.11 |
4.31 ± 0.10 |
4.39 ± 0.12 |
4.30 ± 0.10 |
|
HB |
12.0 ± 0.2 |
12.4 ± 0.4 |
12.0 ± 0.2 |
12.5 ± 0.3* |
12.2 ± 0.3 |
12.1 ± 0.3 |
12.3 ± .2 |
12.2 ± 0.3 |
|
ESR |
29.0 ± 3.6 |
32.4 ± 6.0 |
35.0 ± 3.5 |
30.5 ± 4.8 |
31.7 ± 4.2 |
40.7 ± 6.2 |
26.5 ± 3.6 |
22.2 ± 3.2 |
|
SGPT |
28.8 ± 1.9 |
27.7 ± 2.4 |
23.6 ± 1.9 |
29.3 ± 4.5 |
24.5 ± 1.6 |
25.6 ± 1.7 |
24.9 ± 1.1 |
26.4 ± 3.3 |
|
CRE |
0.98 ± 0.04 |
0.97 ± 0.05 |
1.4 ± 0.4 |
0.9 ± 0.04 |
1.7 ± 0.7 |
1.0 ± 0.03 |
1.67 ± 0.69 |
1.01 ± 0.05 |
|
|
||||||||
|
Data expressed as a mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. Neu = neutrophils %, Bas = basophils %, Eos = eosinophils %, Lym = lymphocytes %, Mon = monocytes %, WBC = white blood cells per mm3, RBC = red blood cells 106 × mm3, HB = hemoglobin gm/dl, ESR = erythrocyte sedimentation rate mm, SGPT = IU/L, CRE = creatinine mg/dl. Using unpaired t test, the following descriptors describe a significant difference from baseline, * p < 0.05. |
||||||||
|
Miller et al. Journal of Inflammation 2005 2:11 doi:10.1186/1476-9255-2-11 |
||||||||
